Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Ferring Ventures SA maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. A single distinct examiner, MARCIA STEPHENS NOBLE, is responsible for this 1 pending office action. Prosecution is situated in 1 distinct art unit. The current prosecution activity for the company is concentrated under this one examiner.
The 1 pending office action defines the current scale of the company's prosecution activity. Because the work is localized in the Biotechnology & Pharmaceuticals technology area, the company's efforts are focused on a single technical field. MARCIA STEPHENS NOBLE, as the busiest examiner with 1 pending office action, handles all active matters for the portfolio. This 1 distinct examiner and 1 distinct art unit structure allows the company to avoid the complexity of managing multiple prosecution styles or differing art unit practices across its current applications.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOBLE, MARCIA STEPHENS | 1 | 67.2% | +39.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18002585 | IMPROVED ADENO-ASSOCIATED VIRUS GENE THERAPY VECTORS | NOBLE, MARCIA STEPHENS | — |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18002585 | IMPROVED ADENO-ASSOCIATED VIRUS GENE THERAPY VECTORS | NOBLE, MARCIA STEPHENS | 1632 | §112 | Non-Final OA | — | Pending | Jul 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFerring Ventures SA has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Marcia Stephens Noble has the most, with 1 of Ferring Ventures SA's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.